Phase 3 Readout

Phase 3 Topline: An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900, an Oral Plasma Kallikrein

Indication
Hereditary Angioedema

Other upcoming events for KALV

Patent ExpiryPatent/Exclusivity Expiry: EKTERLY

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900, an Oral Plasma Kallikrein — KALV Phase 3 Readout | BioSniper